{"id":2412,"date":"2018-05-23T00:00:00","date_gmt":"2018-05-23T00:00:00","guid":{"rendered":"http:\/\/centogene.vl22350.dinaserver.com\/2412"},"modified":"2018-05-23T00:00:00","modified_gmt":"2018-05-23T00:00:00","slug":"colaboracao-no-desenvolvimento-de-medicamentos-com-a-orphazyme","status":"publish","type":"post","link":"https:\/\/www.centogene.com\/pt\/drug-development-collaboration-with-orphazyme\/","title":{"rendered":"Colabora\u00e7\u00e3o no desenvolvimento de medicamentos com a Orphazyme"},"content":{"rendered":"<p>A CENTOGENE, l\u00edder mundial em elucidar a gen\u00e9tica de doen\u00e7as raras para pacientes, m\u00e9dicos e parceiros farmac\u00eauticos, anunciou hoje uma colabora\u00e7\u00e3o para o desenvolvimento cl\u00ednico com a Orphazyme A\/S (CPH: ORPHA) para melhorar a vida de pacientes e fam\u00edlias que convivem com a doen\u00e7a de Gaucher neuronop\u00e1tica, uma doen\u00e7a rara, heredit\u00e1ria, progressiva e debilitante de armazenamento lisoss\u00f4mico.<\/p>\n<p>Nos termos do acordo, a CENTOGENE est\u00e1 apoiando os esfor\u00e7os da Orphazyme em ensaios cl\u00ednicos na \u00cdndia para o uso da pequena mol\u00e9cula arimoclomol no tratamento da doen\u00e7a de Gaucher neuronop\u00e1tica.<\/p>\n<p>\u201cSer capaz de monitorar a melhora do tratamento em um ensaio cl\u00ednico \u00e9 uma capacidade crucial para a ind\u00fastria farmac\u00eautica atualmente. Com nossa profunda experi\u00eancia em identifica\u00e7\u00e3o de biomarcadores e desenvolvimento de ferramentas de diagn\u00f3stico, combinada com nosso amplo conhecimento em doen\u00e7as raras e alcance global, estamos em uma posi\u00e7\u00e3o ideal para sermos o parceiro preferencial da Orphazyme e de desenvolvedores de medicamentos em todo o mundo\u201d, disse o Dr. Arndt Rolfs, CEO e fundador da CENTOGENE.<\/p>\n<p>A CENTOGENE \u00e9 respons\u00e1vel pelo processamento e an\u00e1lise de diversos tipos de amostras de pacientes participantes do estudo, incluindo plasma, l\u00edquido cefalorraquidiano e amostras de sangue seco coletadas com o CentoCard\u00ae da CENTOGENE. Al\u00e9m disso, a CENTOGENE desenvolveu e est\u00e1 utilizando o biomarcador mais sens\u00edvel e validado para a doen\u00e7a de Gaucher, o lysoGb1, como ferramenta de monitoramento durante o estudo.<\/p>\n<h2 class=\"h3\"><strong>Sobre a doen\u00e7a de Gaucher<\/strong><\/h2>\n<p>A doen\u00e7a de Gaucher \u00e9 uma doen\u00e7a metab\u00f3lica heredit\u00e1ria rara. Devido \u00e0 defici\u00eancia da enzima glicocerebrosidase, mol\u00e9culas de gordura contendo a\u00e7\u00facar, chamadas glicolip\u00eddios, se acumulam nos lisossomos das c\u00e9lulas. Os sintomas da doen\u00e7a de Gaucher incluem aumento anormal do f\u00edgado e\/ou ba\u00e7o (hepatoesplenomegalia), anemia, trombocitopenia (aumento da coagula\u00e7\u00e3o sangu\u00ednea) e anormalidades esquel\u00e9ticas. Os sintomas variam muito de paciente para paciente, o que representa um desafio para o desenvolvimento cl\u00ednico de novas terapias. Os aspectos neurol\u00f3gicos da doen\u00e7a apresentam um futuro incerto em rela\u00e7\u00e3o \u00e0 qualidade de vida e \u00e0 expectativa de vida. Estima-se que entre 10.000 e 15.000 pessoas nos Estados Unidos e na Europa sejam afetadas pela doen\u00e7a de Gaucher.<\/p>\n<h2 class=\"h3\"><strong>Sobre a CENTOGENE<\/strong><\/h2>\n<p>A CENTOGENE utiliza o poder do conhecimento gen\u00e9tico para melhorar a qualidade de vida de pacientes com doen\u00e7as gen\u00e9ticas. Conseguimos isso por meio do conhecimento gerado por nossos servi\u00e7os globais de testes diagn\u00f3sticos, que incorporam a diversidade global, o banco de dados propriet\u00e1rio l\u00edder mundial em interpreta\u00e7\u00e3o gen\u00e9tica humana, o CentoMD\u00ae, e solu\u00e7\u00f5es para empresas farmac\u00eauticas que desenvolvem medicamentos \u00f3rf\u00e3os que transformam vidas.<\/p>\n<p>Como uma das maiores e mais diversificadas empresas de testes gen\u00e9ticos do mundo, a CENTOGENE dedica-se a transformar a ci\u00eancia da informa\u00e7\u00e3o gen\u00e9tica em solu\u00e7\u00f5es e esperan\u00e7a para pacientes e suas fam\u00edlias.<\/p>\n<p><a class=\"btn btn-secondary btn-sm\" href=\"https:\/\/www.centogene.com\/pt\/\" target=\"_blank\" title=\"Mais sobre Centogene\">www.centogene.com<\/a>&nbsp;<a class=\"btn btn-secondary btn-sm\" href=\"https:\/\/www.centoMD.com\" target=\"_blank\" title=\"Saiba mais sobre CentoMD\">www.centoMD.com<\/a>&nbsp;<\/p>\n<h2 class=\"h3\"><strong>Sobre a Orphazyme A\/S<\/strong><\/h2>\n<p>A Orphazyme \u00e9 uma empresa biofarmac\u00eautica focada em levar tratamentos inovadores a pacientes que vivem com doen\u00e7as raras, debilitantes ou que amea\u00e7am a vida. Nossa pesquisa concentra-se no desenvolvimento de terapias para doen\u00e7as causadas pelo dobramento incorreto de prote\u00ednas e disfun\u00e7\u00e3o lisoss\u00f4mica. O arimoclomol, principal candidato da empresa, est\u00e1 em desenvolvimento cl\u00ednico para quatro doen\u00e7as raras: Doen\u00e7a de Niemann-Pick tipo C, Doen\u00e7a de Gaucher, Miosite por Corpos de Inclus\u00e3o Espor\u00e1dica e Esclerose Lateral Amiotr\u00f3fica. A empresa, com sede na Dinamarca, est\u00e1 listada na Nasdaq Copenhagen (ORPHA.CO). Para mais informa\u00e7\u00f5es, visite [link para o site da empresa].&nbsp; <a href=\"http:\/\/www.orphazyme.com\" target=\"_blank\" title=\"Obtenha mais informa\u00e7\u00f5es\">www.orphazyme.com<\/a>&nbsp;<\/p>","protected":false},"excerpt":{"rendered":"<p>A CENTOGENE anuncia colabora\u00e7\u00e3o com a Orphazyme para o desenvolvimento de um medicamento para a doen\u00e7a de Gaucher neuronop\u00e1tica.<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2412","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Drug development collaboration with Orphazyme | CENTOGENE<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.centogene.com\/pt\/colaboracao-no-desenvolvimento-de-medicamentos-com-a-orphazyme\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Drug development collaboration with Orphazyme | CENTOGENE\" \/>\n<meta property=\"og:description\" content=\"CENTOGENE Announces Drug Development Collaboration with Orphazyme in Neuronopathic Gaucher Disease\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.centogene.com\/pt\/colaboracao-no-desenvolvimento-de-medicamentos-com-a-orphazyme\/\" \/>\n<meta property=\"og:site_name\" content=\"CENTOGENE\" \/>\n<meta property=\"article:published_time\" content=\"2018-05-23T00:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"740\" \/>\n\t<meta property=\"og:image:height\" content=\"416\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"admincg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"admincg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/drug-development-collaboration-with-orphazyme\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/drug-development-collaboration-with-orphazyme\\\/\"},\"author\":{\"name\":\"admincg\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\"},\"headline\":\"Drug development collaboration with Orphazyme\",\"datePublished\":\"2018-05-23T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/drug-development-collaboration-with-orphazyme\\\/\"},\"wordCount\":493,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/drug-development-collaboration-with-orphazyme\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/drug-development-collaboration-with-orphazyme\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/drug-development-collaboration-with-orphazyme\\\/\",\"name\":\"Drug development collaboration with Orphazyme | CENTOGENE\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\"},\"datePublished\":\"2018-05-23T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/drug-development-collaboration-with-orphazyme\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/drug-development-collaboration-with-orphazyme\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/drug-development-collaboration-with-orphazyme\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.centogene.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Drug development collaboration with Orphazyme\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"name\":\"CENTOGENE\",\"description\":\"Guiding Precision Medicine\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.centogene.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\",\"name\":\"CENTOGENE\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"contentUrl\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"width\":246,\"height\":246,\"caption\":\"CENTOGENE\"},\"image\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/centogene\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UClZxtN_laC1_ZtCdxkasdPQ\",\"https:\\\/\\\/www.instagram.com\\\/_centogene_\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\",\"name\":\"admincg\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/pt\\\/author\\\/admincg\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Colabora\u00e7\u00e3o no desenvolvimento de medicamentos com a Orphazyme | CENTOGENE","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.centogene.com\/pt\/colaboracao-no-desenvolvimento-de-medicamentos-com-a-orphazyme\/","og_locale":"pt_BR","og_type":"article","og_title":"Drug development collaboration with Orphazyme | CENTOGENE","og_description":"CENTOGENE Announces Drug Development Collaboration with Orphazyme in Neuronopathic Gaucher Disease","og_url":"https:\/\/www.centogene.com\/pt\/colaboracao-no-desenvolvimento-de-medicamentos-com-a-orphazyme\/","og_site_name":"CENTOGENE","article_published_time":"2018-05-23T00:00:00+00:00","og_image":[{"width":740,"height":416,"url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp","type":"image\/webp"}],"author":"admincg","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"admincg","Est. tempo de leitura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.centogene.com\/drug-development-collaboration-with-orphazyme\/#article","isPartOf":{"@id":"https:\/\/www.centogene.com\/drug-development-collaboration-with-orphazyme\/"},"author":{"name":"admincg","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b"},"headline":"Drug development collaboration with Orphazyme","datePublished":"2018-05-23T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.centogene.com\/drug-development-collaboration-with-orphazyme\/"},"wordCount":493,"commentCount":0,"publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"articleSection":["Uncategorized"],"inLanguage":"pt-BR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.centogene.com\/drug-development-collaboration-with-orphazyme\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.centogene.com\/drug-development-collaboration-with-orphazyme\/","url":"https:\/\/www.centogene.com\/drug-development-collaboration-with-orphazyme\/","name":"Colabora\u00e7\u00e3o no desenvolvimento de medicamentos com a Orphazyme | CENTOGENE","isPartOf":{"@id":"https:\/\/www.centogene.com\/#website"},"datePublished":"2018-05-23T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.centogene.com\/drug-development-collaboration-with-orphazyme\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.centogene.com\/drug-development-collaboration-with-orphazyme\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.centogene.com\/drug-development-collaboration-with-orphazyme\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.centogene.com\/"},{"@type":"ListItem","position":2,"name":"Drug development collaboration with Orphazyme"}]},{"@type":"WebSite","@id":"https:\/\/www.centogene.com\/#website","url":"https:\/\/www.centogene.com\/","name":"CENTOGENE","description":"Orientando a Medicina de Precis\u00e3o","publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.centogene.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/www.centogene.com\/#organization","name":"CENTOGENE","url":"https:\/\/www.centogene.com\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","contentUrl":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","width":246,"height":246,"caption":"CENTOGENE"},"image":{"@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/centogene","https:\/\/www.youtube.com\/channel\/UClZxtN_laC1_ZtCdxkasdPQ","https:\/\/www.instagram.com\/_centogene_\/"]},{"@type":"Person","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b","name":"admincg","url":"https:\/\/www.centogene.com\/pt\/author\/admincg\/"}]}},"_links":{"self":[{"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/posts\/2412","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/comments?post=2412"}],"version-history":[{"count":0,"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/posts\/2412\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/media?parent=2412"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/categories?post=2412"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/tags?post=2412"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}